|Actelion Ltd -- USA Stock|| |
USD 70 0.16 0.23%
Mr. Thomas Widman is CoFounder at Actelion Ltd. He is a cardiologist educated at Universitat Heidelberg and Paris in Medicine and Computer Science with further training at the University Hospital in Geneva. He later spent seven years at the University of California, San Diego, as Assistant Professor of Medicine and Cardiovascular Associate. During his nine years at F. HoffmannLa Roche, he was responsible for the worldwide clinical development of the company cardiovascular portfolio. He was chairman of F. HoffmannLa Roche cardiovascular strategy team and led an international cardiovascular development team of over 60 people in Europe and the United States. In 1996, he founded Hesperion. Due to his continuing interest in strategic RD and other management topics, he has also attended business courses at INSEAD. As founding member of the Company, he was the Company first Chief Executive Officer and then held the position of Vice Chairman of the Board until spring 2003. He continues to work in close association with the Actelion senior management.
41 61 565 65 65 http://www.actelion.com
The company has return on total asset (ROA)
of 23.87 %
which means that it generated profit of $23.87 on every $100 spent on asset. This is very large. Similarly, it shows return on equity (ROE)
of 47.08 %
meaning that it generated $47.08 on every $100 dollars invested by stockholders.
Actelion Ltd, a biopharmaceutical company, discovers, develops, and commercializes drugs for unmet medical needs. Actelion Ltd (ALIOY) is traded on OTC Market in USA. It is located in Allschwil, and employs 2,500 people.